The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - A decision analysis

Thrombosis and Haemostasis

Volumn 92, Issue 3, 2004, Pages 590-597

  You, Joyce H S ^a   Chan, Fredric W H ^a   Wong, Raymond S M ^b   Cheng, Gregory ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cost effectiveness; CYP2C9; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEALTH CARE COST; HEALTH CARE QUALITY; HEMATURIA; HEMOPTYSIS; HUMAN; INTENSIVE CARE; LUNG EMBOLISM; MEDICAL DECISION MAKING; MEDICAL LITERATURE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; SIMULATION; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 4544361864     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-03-0161     Document Type: Article

References (52)

1. Hirsch H, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
2. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin - nature or nuture? Clin Pharmacol Ther 2001; 70: 159-64.
3. James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704-6.
4. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinetics 1986; 11: 483-504.
5. Chan E, McLachlan A, O'Reilly R, et al. Stereochemical aspects of warfarin drug interactions. Use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994; 56: 286-94.
6. Haber LT, Maier A, Gentry PR, et al. Genetic polymorphisms in assessing interindividual variability in delivered dose. Reg Toxicol Pharmacol 2002; 35: 177-97.
7. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP 2C9 and CYPC19 genotypes. Clin pharmacol Ther 1998; 63: 519-28.
8. Scordo MG, Pengo V, Spina E, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-10.
9. Human Cytochrome P450 (CYP) Allele Nomenclature Committee http://www.imm.ki.se/CYPalleles/ (assessed on 5 March 04)
10. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63.
11. Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-70.
12. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
13. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
14. Higashi MK, Veenstra DL, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287 (13): 1690-8
15. Ogg MS, Brennan B, Meade T, et al. CYP2C9*3 allelic variant and bleeding complications. Lancet 1999; 354: 1124.
16. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87-94.
17. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118: 511-20.
18. You JHS, Chan FWH, Wong RSM, et al. Cost-effectiveness of two models of management for patients on chronic warfarin therapy - A Markov model analysis. Thromb Haemost 2003; 90: 1106-11.
19. Tabrizi AR, Zehnbauer BA, Borecki IB. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002; 194: 267-73.
20. Scordo MG, Aklillu E, Yasar U. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-50.
21. Freeman BD, Zehnbauer BA, McGrath S. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000; 128: 281-5.
22. Takahashi H, Wilkinson GR, Caraco Y. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003; 73: 253-63.
23. Margaglione M, Colaizzo D, D'Andrea G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
24. Yasar U, Eliasson E, Dahl ML. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254: 628-31.
25. Aynacioglu AS, Brockmöller J, Bauer S. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-15.
26. Garcia Martin E, Martinez C, Ladero JM. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 2001; 57: 47-9.
27. Holm T, Lassen JF, Husted SE, et al. A randomized controlled trial of shared care versus routine care for patients receiving oral anticoagulant therapy. J Intern Med 2002; 252: 322-31.
28. Poli D, Antonucci E, Lombardi A, et al. Low rate of bleeding and thrombotic complications of oral anticoagulant therapy independent of age in the real-practice of an anticoagulation clinic. Blood Coagul Fibrinolysis 2003; 14: 269-75.
29. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
30. Errichette AM, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. Arch Intern Med 1984; 144: 1966-8.
31. Charney R, Leddomado E, Rose DN, et al. Anticoagulation clinics and the monitoring of anticoagulation therapy. Int J Cardiol 1988; 18: 197-206.
32. Searbrook GR, Karp D, Schmitt DD, et al. An outpatient anticoagulation protocol managed by a vascular nurse-clinician. Am J Surg 1990; 160: 501-5.
33. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulation therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-17.
34. Cortelazzo S, Finazzi G, Viero P, et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost 1993; 69: 316-20.
35. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7.
36. Beyth RJ, Quinn L, Landefeld CS. A multi-component intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized clinical trial. Ann Intern Med 2000; 133: 687-95.
37. Centers for Medicare & Medicaid Services. http://cms.hhs.gov/statistics/medpar/default.asp (assessed on June 1, 2003)
38. Menzin J, Boulanger L, Hauch O, et al. The cost of warfarin monitoring in anticoagulation clinics: A multi-site managed case study. Value in Health 2002; 5: 165.
39. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9.
40. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP 2C9 polymorphism in a Japanese population. Pharmacogenetics 1997; 7: 405-9.
41. Wang SL, Huang J, Lai MD, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995; 5: 37-42.
42. Yoon YR, Shon JH, Kim MK, et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-80.
43. Ensom, MHH, Chang TKH, Patel P. Pharmacogenetics: The therapeutic drug monitoring of the Future? Clin Pharmacokinet 2001; 40: 783-802.
44. Krynetski EY, Evans WE. Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet 1998; 63: 11-6.
45. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (HERCEPTIN) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58: 2825-31.
46. Farlow MR, Lahiri DK, Poirier J, et al. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann NY Acad Sci 1996; 802: 101-10.
47. Palareti G, Manotti C, DAngelo A, et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997; 78: 1438-43.
48. Hiratsuka M, Agatsuma Y, Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol Genet Metab 1999; 68: 357-62.
49. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1253-8.
50. Naglie IG, Detsky AS. Treatment of chronic nonvalvular atrial fibrillation in the elderly: a decision analysis. Med Decis Making 1992; 12: 239-49.
51. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making 1993; 13: 89-102.
52. Thomson R, Parkin D, Eccles M, et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. BMJ 2000; 355: 956-62.